



Journal of the British Cardiovascular Society

### Guidelines for Authors and Reviewers

Full instructions are available online at <http://heart.bmj.com/pages/authors>. Articles must be submitted electronically <https://mc.manuscriptcentral.com/heart>. Authors retain copyright but are required to grant *Heart* an exclusive licence to publish (<http://authors.bmj.com/submitting-your-paper/copyright-and-authors-rights/>).

### Editorial Office

*Heart*, BMJ Publishing Group  
BMA House, Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0) 20 7383 6622  
E: [info.heart@bmj.com](mailto:info.heart@bmj.com)  
Twitter: @Heart\_BMJ  
ISSN: 1355-6037 (print)  
ISSN: 1468-201X (online)  
Impact factor: 5.213

**Disclaimer:** The Editor of *Heart* has been granted editorial freedom and *Heart* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *Heart* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *Heart* does not imply endorsement. Neither *British Cardiovascular Society* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *Heart* (except for liability which cannot be legally excluded).

**Copyright:** © 2021 BMJ Publishing Group Ltd & British Cardiovascular Society. All rights reserved; no part of this publication may be reproduced in any form without permission.

*Heart* is published by BMJ Publishing Group Ltd, typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Heart*, ISSN 1355-6037 (USPS 2154) is published bimonthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Heart*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square WC1H 9HR London. Air Business Ltd is acting as our mailing agent.



## Heartbeat

**1103** Heartbeat: is postmenopausal hormone therapy a risk factor or preventative therapy for cardiovascular disease in women?  
*C M Otto*

## Editorials

- 1106** Are we there yet? Menopausal hormone therapy for primary cardiovascular disease prevention  
*R Thamman*
- 1109** Early stopping of a randomised trial for efficacy: a medical, ethical and regulatory challenge  
*A Darmon, G Ducrocq*
- 1111** Ticagrelor versus prasugrel for PCI-managed myocardial infarction: the battle of the giants continues  
*R F Storey*
- 1113** Survival after surgical aortic valve replacement in patients with bicuspid aortic valve disease  
*M Jahangiri*

## Reviews

- 1115** Postmenopausal hormone therapy for cardiovascular health: the evolving data  
*F L Gersh, J H O'Keefe, C J Lavie*
- 1123** Metabolic phenotyping and cardiovascular disease: an overview of evidence from epidemiological settings  
*A Iliou, E Mikros, I Karaman, F Elliott, J L Griffin, I Tzoulaki, P Elliott*

## Cardiac risk factors and prevention

**1130** Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease  
*G R Dagenais, L Dyal, J J Bosch, D P Leong, V Aboyans, S D Berkowitz, D L Bhatt, S J Connolly, K A A Fox, E Muehlhofer, J L Probstfield, P Widimsky, B R Winkelmann, S Yusuf, J W Eikelboom*

## Congenital heart disease

**1138** Haemodynamic determinants of improved aerobic capacity after tricuspid valve surgery in Ebstein anomaly  
*A Egbe, W Miranda, H Connolly, J Dearani*

## Coronary artery disease

**1145** Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention  
*D Venetsanos, E Träff, D Erlinge, E Hagström, J Nilsson, L Desta, B Lindahl, L Mellbin, E Omerovic, K E Szummer, S Zwackman, T Jernberg, J Alfredsson*

**1152** Risk for cardiovascular events following 'microsize' versus usual myocardial infarctions  
*Z I Almarzooq, L D Colantonio, P M Okin, J S Richman, T M Brown, E B Levitan, J Bryan, M M Safford*

## Special populations

**1160** Survival and risk of recurrence of takotsubo syndrome  
*C Lau, S Chiu, R Nayak, B Lin, M-S Lee*

## Valvular heart disease

**1167** Relative survival after aortic valve surgery in patients with bicuspid aortic valves  
*N Glaser, V Jackson, P Eriksson, U Sartipy, A Franco-Cereceda*

## Education in Heart

**1173** Cardiac manifestations of rheumatological disease: a synopsis for the cardiologist  
*G Sen, P Gordon, D M Sado*

## Cardiology in focus

**1182** Working with radiation in pregnancy: a guide for cardiologists  
*A Wood, S T Hussain*

MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals open access scheme. See <http://heart.bmj.com/site/about/guidelines.xhtml#open>



Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics  
[www.publicationethics.org](http://www.publicationethics.org)



When you have finished with this magazine please recycle it.



The online version of this article contains multiple choice questions hosted on BMJ Learning.

**Image challenge**

**1166** Patient manifested as left ventricular non-compaction  
*L Wang, D Yang, Y Chen*

**Electronic page**

**e5** Correction: *Effects of continue exhaustive running on rat cardiovascular ultrastructure, myocardial apoptosis and vessel function*